Biopure Hemopure New User Fee Likely In November; FDA Requests Data
This article was originally published in Pharmaceutical Approvals Monthly
FDA’s PDUFA date for Biopure’s hemoglobin-based oxygen carrier Hemopure will likely be in November following the agency’s request for further clarification on the BLA.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class